2808

antibody from Cell Signaling Technology, Inc

Targeting: BIRC5 API4, EPR-1, survivin

Western blot (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunoprecipitation (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Flow cytometry (Data presented on provider website)

Antibody Data

Product number

2808

Provider

Cell Signaling Technology, Inc

Proper citation

Cell Signaling Technology Cat#2808, RRID:AB_2063948

Product name

Survivin (71G4B7) Rabbit mAb

Antibody type

Monoclonal

Reactivity

Human, Mouse, Rat

Host

Rabbit

Storage

-20°C

References

Submitted references

SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.

Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, Renner M, Kirfel J, Steiner S, Huss S, Koch A, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Waha A, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W
Oncogene 2014 Oct 16;33(42):5006-16

---

Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.

Jane EP, Premkumar DR, Pollack IF
Molecular cancer therapeutics 2011 Jan;10(1):198-208

---

Escherichia coli subtilase cytotoxin induces apoptosis regulated by host Bcl-2 family proteins Bax/Bak.

May KL, Paton JC, Paton AW
Infection and immunity 2010 Nov;78(11):4691-6

---

CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.

Roca H, Varsos ZS, Pienta KJ
Neoplasia (New York, N.Y.) 2009 Dec;11(12):1309-17